Therefore, this finding suggests that therapies designed to degrade the CXCR3 protein, such as proteolysis-targeting chimeras (PROTAC), may be more effective in achieving a comprehensive anti-tumor effect compared to conventional antagonists [181,182]. This evidence concerns the gene CXCR3 and neoplasm.